^
Association details:
| Biomarker: | EGFR negative + ALK negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Endostar (recombinant human endostatin) (VEGF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer: A real-world study.
Published date:
05/25/2023
Excerpt:
...we aimed to evaluate the effectiveness and safety of endostatin combined with PD-1 antibody plus chemotherapy as the first-line treatment for locally advanced or distant metastatic NSCLC with EGFR/ALK-negative….The median PFS and OS were 22.0 months (95% confidence interval [CI]: 16.6-27.4 months) and 31.0 months (95% CI: 23.4 months-not reached [NR]), respectively, with a median follow-up of 21.4 months (range, 8.3-44.4 months)....In the real-world scenario, endostatin combination with PD-1 antibody plus chemotherapy obtained encouraging efficacy and favorable safety in advanced or metastatic NSCLC.
Secondary therapy:
Chemotherapy + PD1 inhibitor
DOI:
10.1200/JCO.2023.41.16_suppl.e20564
